ArticleBiochemical genetics2026
Synergistic Targeting of Hepatocellular Carcinoma via Novel Regorafenib Combinations with Diosmin, Sulfasalazine, or Rosuvastatin.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling regorafenib resistance: metabolic reprogramming, tumor plasticity, and novel approaches to overcome therapy failure.Archives of pharmacal research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), the most common liver cancer, has limited treatment options. The author investigated novel combinations of regorafenib (Reg) with diosmin (Dio), sulfasalazine (SZZ), or rosuvastatin (Ros) to enhance anti-HCC efficacy. Each agent potentiated Reg activity via distinct pathway modulation: Reg/Dio inhibited Akt/m-TOR and RAF/ERK; Reg/SZZ suppressed Akt/m-TOR and NF-κB; and Reg/Ros suppressed JAK/STAT3 and RAF/ERK. These findings demonstrate synergistic potential by combining Reg with drugs possessing complementary anti-inflammatory, cholesterol-lowering, or cytotoxic activities, offering promising multi-targeted therapeutic strategies for HCC.
Indexed as
Identifiers
40423912What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.